Schiff Hardin LLP Represents AuraSense Therapeutics in Series B Financing

News

Schiff Hardin LLP Represents AuraSense Therapeutics in Series B Financing

News Release |

Attorneys from Schiff Hardin's Private Companies Group advised client AuraSense Therapeutics, LLC in the successful completion of its Series B financing round.

AuraSense Therapeutics is a biopharmaceutical company founded by Dr. Chad A. Mirkin, Director of Northwestern University's International Institute of Nanotechnology, to commercialize spherical nucleic acid (SNATM) constructs as gene regulation- and chemo-therapeutics for a variety of diseases, including applications in oncology, dermatology, neurobiology, and for cardiovascular disorders. Terms of the private offering transaction were not disclosed. The company's press release announcing the completion of the financing is here: http://www.aurasensetherapeutics.com/media-library/press-releases/aurasense-therapeutics-secures-series-b-equity-investment.aspx. The company's scientific founders and their developments have been the subject of over 70 international and national awards, over 500 publications, and over 450 patents. For more information, visit www.aurasensetherapeutics.com.

Private Companies Group leader Matthew Galo led the Schiff Hardin team, with Robert R. Pluth Jr. (Tax), Alexander B. Young (Corporate and Securities), Chris L. Bollinger (Intellectual Property) and Edward Spacapan Jr. (Employee Benefits and Executive Compensation).